Axsome director granted 1,721 RSUs

Mahony Susan reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Mahony Susan reported acquisition or exercise transactions in this Form 4 filing.

Axsome Therapeutics, Inc. director Susan Mahony received a grant of 1,721 restricted stock units as equity compensation. Each RSU represents a right to receive one share of Axsome common stock at no cash cost. The RSUs vest in full on the one-year anniversary of the grant date, aligning her compensation with future company performance. After this award, she holds 1,721 RSUs directly.

Insider Trade Summary

Grant/Award: 1,721 shares

Grant/Award 1 txn

Insider Mahony Susan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	1,721	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 1,721 contracts (Direct)

Footnotes (2)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2. The RSUs vest in full on the one-year anniversary of the date of grant.

Key Figures

RSUs granted: 1,721 units RSU price: $0.00 per unit Underlying shares: 1,721 shares +1 more

4 metrics

RSUs granted 1,721 units Restricted stock units awarded to director on grant date

RSU price $0.00 per unit Grant price for restricted stock units

Underlying shares 1,721 shares Common shares underlying the RSU award

Holdings after award 1,721 RSUs Total RSUs directly held following transaction

Key Terms

Restricted Stock Units, RSU, contingent right, vest

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSU financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

contingent right financial

"represents a contingent right to receive one share of the Issuer's common stock"

vest financial

"The RSUs vest in full on the one-year anniversary of the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Axsome Therapeutics (AXSM) report for Susan Mahony?

Axsome Therapeutics reported that director Susan Mahony received 1,721 restricted stock units as equity compensation. Each unit converts into one share of common stock, giving her a future ownership interest that aligns her incentives with shareholder outcomes over time.

How many Axsome Therapeutics (AXSM) RSUs were granted in this Form 4 filing?

The filing shows a grant of 1,721 restricted stock units to director Susan Mahony. These RSUs represent a future right to receive 1,721 shares of Axsome common stock, subject to vesting conditions described in the disclosure footnotes for the award.

When do Susan Mahony’s Axsome Therapeutics (AXSM) RSUs vest?

The restricted stock units granted to Susan Mahony vest in full on the one-year anniversary of the grant date. This single cliff-vesting schedule encourages continuity of service and ties the economic value of the award to Axsome’s performance over the coming year.

Does the Axsome Therapeutics (AXSM) RSU grant involve a cash purchase or exercise price?

The RSU grant carries a stated price of zero per unit, meaning no cash payment is required from Susan Mahony to receive shares upon vesting. Instead, the award functions as stock-based compensation granted by the company for her board service.

What is Susan Mahony’s Axsome Therapeutics (AXSM) equity position after this RSU grant?

After the reported transaction, Susan Mahony directly holds 1,721 restricted stock units. Each RSU represents a contingent right to receive one share of Axsome common stock, so her potential share ownership will depend on vesting and any future equity awards or changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/09/2026 - 05:18 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahony Susan

(Last)

(First)

(Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/05/2026		A		1,721		⁽²⁾	⁽²⁾	Common Stock	1,721	$0	1,721	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs vest in full on the one-year anniversary of the date of grant.

	/s/ Nick Pizzie, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR